Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie recently updated its clinical study titled, A Phase 1 First-in-Human, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABBV-303, as Monotherapy and in Combination With Budigalimab (ABBV-181), in Adult Subjects With Advanced Solid Tumors. The study aims to assess the safety and efficacy of ABBV-303, both alone and with Budigalimab, for treating advanced solid tumors. This research is significant as it explores new treatment avenues for challenging cancer types.
The study involves testing ABBV-303, an investigational drug, as a monotherapy and in combination with Budigalimab, another investigational treatment. Both drugs are administered intravenously to assess their effects on solid tumors.
This Phase 1 study is non-randomized and follows a sequential intervention model without masking, focusing primarily on treatment. It includes multiple treatment arms to evaluate different dosages and combinations.
The study began on November 29, 2023, with its last update submitted on October 24, 2025. However, the study has been terminated, which is a crucial factor for stakeholders to consider.
The termination of this study could impact AbbVie’s stock performance and investor sentiment, as it may affect the company’s pipeline and competitive positioning in the oncology market. Investors should monitor how AbbVie addresses this development and any strategic shifts that may follow.
The study has been terminated, and further details are available on the ClinicalTrials portal.